and recommendation
Regenxbio Inc. (RGNX)
RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
- March 4, 2018 - 11:11am | Analysis, Out and About
- November 3, 2017 - 1:08pm | Earnings, Earnings Q3
- May 5, 2017 - 8:59am | Earnings, Earnings Q1
- March 21, 2017 - 4:58pm | Research Notes, Financings
- March 10, 2017 - 12:00am | Earnings, Earnings Q4
- February 7, 2017 - 12:42pm | Research Notes
- November 2, 2016 - 8:46pm | Earnings, Earnings Q3
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2
- December 30, 2015 - 10:56am | Regulatory
- November 16, 2015 - 10:34am | Earnings Q3
- October 2, 2015 - 7:00am | Research Notes, Regulatory